Get the Stockscreener App
0.9101
4.91%
0.0426
After Hours:
.90
-0.0101
-1.11%
Bioatla Inc stock is traded at $0.9101, with a volume of 750.28K.
It is up +4.91% in the last 24 hours and up +17.45% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.8675
Open:
$0.9
24h Volume:
750.28K
Relative Volume:
0.87
Market Cap:
$53.44M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.3514
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+10.99%
1M Performance:
+17.45%
6M Performance:
+200.66%
1Y Performance:
-56.03%
1-Day Range:
$0.90
$0.9999
1-Week Range:
$0.75
$1.06
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.9101 | 50.94M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Why BioAtla Inc. stock is favored by top institutionsRate Cut & AI Enhanced Trading Signals - newser.com
Will BioAtla Inc. continue its uptrendStock Surge & Safe Swing Trade Setup Alerts - newser.com
How supply chain issues affect BioAtla Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Strategies to average down on BioAtla Inc.2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
How to use a screener to detect BioAtla Inc. breakoutsWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Is BioAtla Inc. reversing from oversold territoryJuly 2025 Recap & Verified Swing Trading Watchlist - newser.com
Real time breakdown of BioAtla Inc. stock performancePrice Action & Low Drawdown Momentum Ideas - newser.com
Understanding BioAtla Inc.’s price movementJuly 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Order flow analysis tools used on BioAtla Inc.Quarterly Profit Report & Weekly High Conviction Ideas - newser.com
How institutional ownership impacts BioAtla Inc. stockJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Technical signs of recovery in BioAtla Inc.Portfolio Performance Report & Low Drawdown Investment Strategies - newser.com
What’s next for BioAtla Inc. stock priceEarnings Miss & Long-Term Growth Plans - newser.com
Applying Elliott Wave Theory to BioAtla Inc.Bull Run & Weekly High Momentum Picks - newser.com
Why BioAtla Inc. stock could outperform in 2025Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Will BioAtla Inc. stock recover after recent dropJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Can technical indicators confirm BioAtla Inc.’s reversalWeekly Stock Recap & High Return Stock Watch Alerts - newser.com
Historical volatility pattern of BioAtla Inc. visualizedMarket Sentiment Review & Fast Gain Stock Trading Tips - newser.com
Why BioAtla Inc. stock is rated strong buyInsider Buying & Short-Term Trading Alerts - newser.com
Will BioAtla Inc. stock keep outperforming rivalsTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Should you wait for a breakout in BioAtla Inc.Bond Market & Community Shared Stock Ideas - newser.com
Can momentum traders help lift BioAtla Inc.2025 Volume Leaders & Growth Focused Entry Reports - newser.com
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewswire
BioAtla, Inc. to Present Clinical Data on AXL-Targeting ADC Mecbotamab Vedotin at SITC 2025 Annual Meeting - Quiver Quantitative
Median OS 21.5 months: BioAtla presents mecbotamab vedotin data in 44 sarcoma patients at SITC - Stock Titan
Detecting price anomalies in BioAtla Inc. with AIWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
Real time alert setup for BioAtla Inc. performanceJuly 2025 Reactions & Technical Entry and Exit Alerts - newser.com
BioAtla (NASDAQ:BCAB) Stock Price Up 3.3% – Time to Buy? - Defense World
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):